Preeklampside stathmin-1: klinik şiddetin potansiyel göstergesi

Abstract

Amaç Preeklampsi (PE), anormal plasentasyon ile ilişkili ve belirgin maternal-fetal morbiditeye yol açan multisistemik bir gebelik komplikasyonudur. Plasental disfonksiyonu ve hastalık şiddetini yansıtabilecek güvenilir biyobelirteçlerin tanımlanması klinik açıdan önemlidir. Bu çalışma, hücre proliferasyonu ve trofoblast invazyonunun düzenleyicisi olan Stathmin-1 (STMN-1) düzeylerinin, ciddi özellikleri olan ve olmayan PE olguları ile sağlıklı gebeler arasında karşılaştırılmasını amaçlamıştır. Yöntemler Bu prospektif, kesitsel çalışmaya 81 gebe kadın dahil edilmiştir: 41’i PE tanılı (22’si ciddi özellik göstermeyen, 19’u ciddi özellik gösteren) ve 40’ı normotansif sağlıklı kontrol grubundandır. Maternal serum STMN-1 düzeyleri, doğrulanmış bir ELISA yöntemi kullanılarak ölçülmüştür. Klinik özellikler, perinatal sonuçlar ve laboratuvar bulguları gruplar arasında karşılaştırılmıştır. Bulgular STMN-1 düzeyleri, PE grubunda (5,99 ± 3,37) kontrol grubuna (8,23 ± 3,42) kıyasla anlamlı olarak daha düşüktü (p = 0,004). Ciddi özellik göstermeyen PE olgularında kontrol grubuna kıyasla STMN-1 düzeyleri daha düşük olma eğiliminde olsa da bu fark istatistiksel olarak anlamlı değildi (p = 0,172). Ciddi özellik gösteren PE olgularında (4,88 ± 2,96), ciddi özellik göstermeyen PE grubuna (6,97 ± 3,46; p = 0,047) ve kontrol grubuna (p = 0,001) kıyasla STMN-1 düzeyleri anlamlı derecede düşüktü. Sonuç Maternal serum Stathmin-1 düzeyleri, özellikle ciddi preeklampsi olgularında belirgin şekilde azalmaktadır. Bu bulgular, STMN-1’in PE’nin tanısında ve şiddetinin değerlendirilmesinde potansiyel bir biyobelirteç olarak kullanılabileceğini düşündürmektedir. Bulguların tanısal ve prognostik değerini doğrulamak için daha geniş ölçekli çalışmalara ihtiyaç vardır.

Keywords

• Stathmin-1
• preeklampsi
• STMN-1
• trofoblast invazyonu

Stathmin-1 as a biomarker in preeclampsia: correlation with clinical severity

Abstract

Aims: Preeclampsia (PE) is a multisystem pregnancy disorder linked to abnormal placentation and significant maternal-fetal morbidity. Identifying reliable biomarkers that reflect placental dysfunction and disease severity remains clinically important. This study aimed to assess maternal serum levels of stathmin-1 (STMN-1), a regulator of cell proliferation and trophoblast invasion, in pregnancies complicated by PE with and without severe features, compared to healthy controls. Methods: This prospective, cross-sectional study included 81 pregnant women: 41 with PE (22 without severe features and 19 with severe features) and 40 normotensive healthy controls. Maternal serum STMN-1 levels were measured using a validated ELISA method. Clinical characteristics, perinatal outcomes, and laboratory findings were compared across groups. Results: STMN-1 levels were significantly lower in the PE group (5.99±3.37) than in controls (8.23±3.42)(p=0.004). Although not statistically significant (p=0.172), levels tended to be lower in PE without severe features compared to controls. STMN-1 levels were significantly lower in PE with severe features (4.88±2.96) than in PE without severe features (6.97±3.46, p=0.047) and controls (p=0.001). Conclusion: Maternal serum STMN-1 levels decrease in PE, particularly in severe cases. These findings suggest that STMN1 may serve as a useful biomarker for identifying and assessing the severity of PE. Further large-scale studies are needed to confirm its diagnostic and prognostic value.

Keywords

• Stathmin-1
• preeclampsia
• STMN-1
• trophoblast invasion

References

1. Karrar SA, Martingano DJ, Hong PL. Preeclampsia. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2024.
2. Torres-Torres J, Espino-Y-Sosa S, Martinez-Portilla R, et al. A narrative review on the pathophysiology of preeclampsia. Int J Mol Sci. 2024; 25(14):7569. doi:10.3390/ijms25147569
3. Kim YJ. Pathogenesis and promising non-invasive markers for preeclampsia. Obstet Gynecol Sci. 2013;56(1):2-7. doi:10.5468/OGS.2013. 56.1.2
4. Krzyszkowska M, Staniczek J, Kondracka A, et al. From biomarkers to the molecular mechanism of preeclampsia-a comprehensive literature review. Int J Mol Sci. 2023;24(17):13252. doi:10.3390/ijms241713252
5. Gruslin A, Lemyre B. Pre-eclampsia: fetal assessment and neonatal outcomes. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):491-507. doi: 10.1016/j.bpobgyn.2011.02.004
6. Clement MJ, Jourdain I, Lachkar S, et al. N-terminal stathmin-like peptides bind tubulin and impede microtubule assembly. Biochemistry. 2005;44:14616-14625. doi:10.1021/bi0512492
7. Chen J, Abi-Daoud M, Wang A, et al. Stathmin 1 is a potential novel oncogene in melanoma. Oncogene. 2013;32(10):1330-1337. doi:10.1038/onc.2012.141
8. Yoshie M, Tamura K, Kogo H. Differential localization of decidual stathmin during pregnancy in rats. Placenta. 2004;25(5):449-455. doi: 10.1016/j.placenta.2003.10.007

9. Tian FJ, Qin CM, Li XC, et al. Decreased stathmin-1 expression inhibits trophoblast proliferation and invasion and is associated with recurrent miscarriage. Am J Pathol. 2015;185(10):2709-2721. doi:10.1016/j.ajpath. 2015.06.010
10. Tamura K, Yoshie M, Nishi H, et al. Expression of stathmin in human uterus and decidualizing endometrial stromal cells. Reproduction. 2006; 132(4):625-636. doi:10.1530/rep.1.01148
11. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135(6):e237-e260. doi:10.1097/AOG. 0000000000003891
12. Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018;13:291-310. doi:10.1016/j.preghy.2018.05.004
13. Semerci SY, Yücel B, Erbaş İM, Günkaya OS, Çetinkaya M. The possible association between neonatal morbidities and amniotic fluid pH and electrolyte levels in infants of preeclamptic mothers. Turk J Pediatr. 2021;63(5):867-874. doi:10.24953/turkjped.2021.05.014
14. Fillion A, Guerby P, Menzies D, et al. Pathological investigation of placentas in preeclampsia (the PEARL study). Hypertens Pregnancy. 2021;40(1):56-62. doi:10.1080/10641955.2020.1866008
15. Ali A, Addley S, Ong S. Three-dimensional indices of renal perfusion in normal pregnancy and pre-eclampsia. Ir J Med Sci. 2019;188(1):173-177. doi:10.1007/s11845-018-1844-8
16. Tjoa ML, Oudejans CB, van Vugt JM, Blankenstein MA, van Wijk IJ. Markers for presymptomatic prediction of preeclampsia and intrauterine growth restriction. Hypertens Pregnancy. 2004;23(2):171-189. doi:10.1081/PRG-120028292
17. Larsson N, Marklund U, Gradin HM, Brattsand G, Gullberg M. Control of microtubule dynamics by oncoprotein 18: dissection of the regulatory role of multisite phosphorylation during mitosis. Mol Cell Biol. 1997;17(9):5530-5539. doi:10.1128/MCB.17.9.5530
18. Bièche I, Maucuer A, Laurendeau I, et al. Expression of stathmin family genes in human tissues: non-neural-restricted expression for SCLIP.Genomics. 2003;81(4):400-410. doi:10.1016/s0888-7543(03) 00031-4
19. Nie L, Zhang C, Song H, et al. Overexpression of stathmin 1 predicts poor prognosis and promotes cancer cell proliferation and migration in ovarian cancer. Dis Markers. 2022;2022:3554100. doi:10.1155/2022/ 3554100
20. Watanabe A, Suzuki H, Yokobori T, et al. Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma. Cancer Sci. 2014;105(6):690-696. doi: 10.1111/cas.12417
21. Zhang X, Ji J, Yang Y, Zhang J, Shen L. Stathmin1 increases radioresistance by enhancing autophagy in non-small-cell lung cancer cells. Onco Targets Ther. 2016;9:2565-2574. doi:10.2147/OTT.S100468
22. Yoshie M, Kashima H, Bessho T, Takeichi M, Isaka K, Tamura K. Expression of stathmin, a microtubule regulatory protein, is associated with the migration and differentiation of cultured early trophoblasts. Hum Reprod. 2008;23(12):2766-2774. doi:10.1093/humrep/den317
23. Lin Y, Li C, Shan B, et al. Reduced stathmin-1 expression in natural killer cells associated with spontaneous abortion. Am J Pathol. 2011;178(2): 506-514. doi:10.1016/j.ajpath.2010.10.005
24. Dayanan R, Bulan DD, Yucel KY. Diagnostic and prognostic role of thrombospondin-4 levels in pre-eclampsia: association with onset type, severity, and perinatal outcome. Int J Gynaecol Obstet. 2025;171(1):345-352. doi:10.1002/ijgo.70456